BioCentury
ARTICLE | Clinical News

Neurocrine down on Phase IIb Tourette syndrome miss

December 12, 2018 7:31 PM UTC

Neurocrine Biosciences Inc. (NASDAQ:NBIX) lost $11.93 (14%) to $73.83 on Wednesday after it said valbenazine missed the primary endpoint in the Phase IIb T-Force GOLD trial to treat Tourette syndrome. The move translates to a loss in market cap of almost $1.1 billion.

In 127 pediatric patients with moderate to severe Tourette syndrome, once-daily oral valbenazine failed to significantly improve motor and phonic tic symptoms as measured by Yale Global Tic Severity Scale (YGTSS) Total Tic Score from baseline to week 12 vs. placebo...